Oncodesign Precision Medicine

Cancer cells
#Acute inflammatory conditions #Immuno-oncology #Oncodesign Precision Medicine #Oncology #Phase I trial

OPM tests first kinase inhibitor in clinic

Oncodesign Precision Medicine (OPM) has announced positive results of a Phase I trial testing the drug candidate OPM-101, administered orally in single ascending doses (SAD) and multiple ascending doses (MAD), in healthy volunteers (HV). OPM-101 is intended for the treatment of resistant and metastatic cancers. Read More

#Cancer Research #News